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TO THE EDITOR:
We have read with great interest the review article by 
Feng and Bucuvalas.(1) They reviewed from a molec-
ular to a clinical point of view all aspects regarding 
immune tolerance (IT) after liver transplantation 
(LT), including all available evidence, comprising 
adult and pediatric, retrospective and prospective 
studies, clinical trials, and even the different IT con-
texts (operational or induced). The success rate of 
immunosuppression (IS) withdrawal in these studies 
varied between 6% and 63%, but was usually approx-
imately 20%-30%.
The biggest Portuguese adult LT unit recently 
reached its 2000th LT. Although there are anecdotal 
cases of patients “involuntarily” going without immu-
nosuppression (for reasons such as patient's unwilling-
ness to take medicine or unacceptable adverse effects), 
a program of IT has not yet been designed. Therefore, 
it would be interesting to think about how to imple-
ment such a program in a “real life” setting, outside the 
context of a clinical trial.
On the basis of the information reviewed in their 
article,(1) namely, the 12 single-center and 2 multi-
center reports on adult operational IT, we propose a 
methodology in a real life setting of selection and eval-
uation of results that would probably improve the only 
moderate outcomes seen until now. One important 
aspect is that patients should have been transplanted 
for >3 years, although the most favorable results are 
seen with >10 years of LT.(2) If the patient is <50 
years, probably more time of transplantation should be 
required; in the Liver Immunosuppression Free Trial 
(LIFT) (NCT02498977) conducted by Sanchez-
Fueyo that is currently enrolling, they propose >6 
years. Another aspect is that patients with autoimmune 
hepatitis and probably hepatitis C infection (because it 
is associated with more fibrosis) should be excluded. 
Finally, it should also be considered as inclusion cri-
teria for normal liver tests, ferritin >30 ng/mL, and a 
liver biopsy with absence of acute or chronic rejection, 
portal inflammation in <50% of portal tracts (unless 
attributable to hepatitis C infection), central perive-
nulitis in <50% of central veins, METAVIR stage I 
or II, and hepatocyte iron accumulation. Patients may 
have been transplanted either with deceased or living 
donor organs because there are not sufficient data to 
affirm that 1 strategy is better than the other. After IS 
withdrawal, patients could be given regular liver tests 
(eg, every 3 months) and at 12 months after discontin-
uation, a liver biopsy would be performed. If there were 
no alterations at this point, the patient could continue 
off IS with frequent monitoring and maybe have a 
liver biopsy 3-5 years later. If there were characteristics 
suggestive of rejection or pronounced inflammation or 
fibrosis, the patient should restart IS.
We hypothesize that with aging and increased inci-
dence of hepatocellular carcinoma and its improved 
survival rates, there may be a larger subset of patients 
who will be eligible for operational IT.
This empirical methodology could be further 
 optimized once studies on biomarkers and IT induc-
tioninterventions show good results and become 
available.
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